Lars Farde

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7801833/publications.pdf

Version: 2024-02-01

147 papers	11,625 citations	26630 56 h-index	29157 104 g-index
153 all docs	153 docs citations	153 times ranked	7876 citing authors

#	Article	IF	Citations
1	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [<scp>¹¹C</scp>]<scp>PBR28</scp> and Machine Learning Analysis. Movement Disorders, 2022, 37, 119-129.	3.9	18
2	Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis. Molecular Psychiatry, 2022, 27, 1233-1240.	7.9	13
3	Decreased 5â€HT_{1A} binding in mild Alzheimer's diseaseâ€”A positron emission tomography study. Synapse, 2022, 76, .	1.2	2
4	Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy. Movement Disorders, 2022, 37, 1776-1778.	3.9	0
5	Synthesis and Preclinical Evaluation of [¹¹C]AZ11895530 for PET Imaging of the Serotonin 1A Receptor. ACS Chemical Neuroscience, 2022, 13, 2078-2083.	3.5	0
6	Preclinical Comparison of the Bloodâ€“brain barrier Permeability of Osimertinib with Other EGFR TKIs. Clinical Cancer Research, 2021, 27, 189-201.	7.0	106
7	Low convergent validity of [11C]raclopride binding in extrastriatal brain regions: A PET study of within-subject correlations with [11C]FLB 457. NeuroImage, 2021, 226, 117523.	4.2	11
8	Brain exposure of the ATM inhibitor AZD1390 in humansâ€”a positron emission tomography study. Neuro-Oncology, 2021, 23, 687-696.	1.2	35
9	Serotonin transporter availability in adults with autismâ€”a positron emission tomography study. Molecular Psychiatry, 2021, 26, 1647-1658.	7.9	27
10	No association between cortical dopamine D2 receptor availability and cognition in antipsychotic-naive first-episode psychosis. NPJ Schizophrenia, 2021, 7, 46.	3.6	3
11	The pro-psychotic metabotropic glutamate receptor compounds fenobam and AZD9272 share binding sites with monoamine oxidase-B inhibitors in humans. Neuropharmacology, 2020, 162, 107809.	4.1	10
12	In response to the letter â€œ[11C]raclopride and extrastriatal binding to D2/3 receptorsâ€• NeuroImage, 2020, 207, 116371.	4.2	2
13	M7. LOWER THALAMIC DOPAMINE D2-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH PSYCHOSIS â€“ A REPLICATION STUDY USING POSITRON EMISSION TOMOGRAPHY. Schizophrenia Bulletin, 2020, 46, S135-S136.	4.3	0
14	Dopamine D1 receptor availability is not associated with delusional ideation measures of psychosis proneness. Schizophrenia Research, 2020, 222, 175-184.	2.0	2
15	High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinsonâ€™s disease cohort. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2407-2416.	6.4	12
16	Quantification and reliability of [11C]VC - 002 binding to muscarinic acetylcholine receptors in the human lung â€” a test-retest PET study in control subjects. EJNMMI Research, 2020, 10, 59.	2.5	5
17	KinfitrÂâ€”Âan open-source tool for reproducible PET modelling: validation and evaluation of test-retest reliability. EJNMMI Research, 2020, 10, 77.	2.5	14
18	Effects of age, BMI and sex on the glial cell marker TSPO â€” a multicentre [11C]PBR28 HRRT PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2329-2338.	6.4	70

#	Article	IF	Citations
19	Pulmonary PET imaging confirms preferential lung target occupancy of an inhaled bronchodilator. EJNMMI Research, 2019, 9, 9.	2.5	9
20	Validity and reliability of extrastriatal [11C]raclopride binding quantification in the living human brain. NeuroImage, 2019, 202, 116143.	4.2	36
21	D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients. International Journal of Neuropsychopharmacology, 2019, 22, 415-425.	2.1	25
22	PET imaging of [11C]PBR28 in Parkinsonâ€™s disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 367-375.	6.4	50
23	Potential for imaging the high-affinity state of the 5-HT1B receptor: a comparison of three PET radioligands with differing intrinsic activity. EJNMMI Research, 2019, 9, 100.	2.5	4
24	Brain neuroreceptor density and personality traits: towards dimensional biomarkers for psychiatric disorders. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20170156.	4.0	24
25	The metabotropic glutamate receptor 5 radioligand [11C]AZD9272 identifies unique binding sites in primate brain. Neuropharmacology, 2018, 135, 455-463.	4.1	13
26	The MINDVIEW project: First results. European Psychiatry, 2018, 50, 21-27.	0.2	19
27	[11C]SCH23390 binding to the D1-dopamine receptor in the human brainâ€”a comparison of manual and automated methods for image analysis. EJNMMI Research, 2018, 8, 74.	2.5	9
28	Test-retest reliability and convergent validity of (R)-[11C]PK11195 outcome measures without arterial input function. EJNMMI Research, 2018, 8, 102.	2.5	21
29	The development of a GPR44 targeting radioligand [11C]AZ12204657 for in vivo assessment of beta cell mass. EJNMMI Research, 2018, 8, 113.	2.5	15
30	GABA _A receptor availability is not altered in adults with autism spectrum disorder or in mouse models. Science Translational Medicine, 2018, 10, .	12.4	41
31	Serotonin concentration enhancers at clinically relevant doses reduce [11C]AZ10419369 binding to the 5-HT1B receptors in the nonhuman primate brain. Translational Psychiatry, 2018, 8, 132.	4.8	11
32	The immune response of the human brain to abdominal surgery. Annals of Neurology, 2017, 81, 572-582.	5.3	87
33	Reliability of volumetric and surface-based normalisation and smoothing techniques for PET analysis of the cortex: A test-retest analysis using [11C]SCH-23390. NeuroImage, 2017, 155, 344-353.	4.2	20
34	GABAA receptor occupancy by subtype selective GABAAÎ±2,3 modulators: PET studies in humans. Psychopharmacology, 2017, 234, 707-716.	3.1	21
35	[11 C]AZ10419096 â€“ a full antagonist PET radioligand for imaging brain 5-HT 1B receptors. Nuclear Medicine and Biology, 2017, 54, 34-40.	0.6	8
36	Characterization of [11C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 308-320.	6.4	7

#	Article	IF	Citations
37	Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain. International Journal of Neuropsychopharmacology, 2017, 20, 683-691.	2.1	25
38	Assessment of simplified ratio-based approaches for quantification of PET [11C]PBR28 data. EJNMMI Research, 2017, 7, 58.	2.5	33
39	Differential Effect of APOE Alleles on Brain Glucose Metabolism in Targeted Replacement Mice: An [18F]FDG-Î¼PET Study. Journal of Alzheimer's Disease Reports, 2017, 1, 169-180.	2.2	9
40	Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 464-471.	2.5	4
41	In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects. Brain, Behavior, and Immunity, 2016, 54, 149-157.	4.1	48
42	Low serotonin1B receptor binding potential in the anterior cingulate cortex in drug-free patients with recurrent major depressive disorder. Psychiatry Research - Neuroimaging, 2016, 253, 36-42.	1.8	21
43	Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using ¹⁸F-FE-PE2I in Healthy Controls and Parkinson Disease Patients. Journal of Nuclear Medicine, 2016, 57, 1529-1534.	5.0	21
44	Neurokinin-3 Receptor Binding in Guinea Pig, Monkey, and Human Brain: In Vitro and in Vivo Imaging Using the Novel Radioligand, [¹⁸F]Lu AF10628. International Journal of Neuropsychopharmacology, 2016, 19, pyw023.	2.1	1
45	Discovery and Preclinical Validation of [11C]AZ13153556, a Novel Probe for the Histamine Type 3 Receptor. ACS Chemical Neuroscience, 2016, 7, 177-184.	3.5	7
46	A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates. Neuropharmacology, 2016, 101, 519-530.	4.1	12
47	¹¹C-carbonylation reactions using gasâ€“liquid segmented microfluidics. RSC Advances, 2015, 5, 88886-88889.	3.6	19
48	TSPO binding may also represent â€˜restingâ€™ microglia. Clinical and Translational Imaging, 2015, 3, 491-492.	2.1	2
49	5â€<scp>HT</scp>_{1B} receptor imaging and cognition: A positron emission tomography study in control subjects and parkinson's disease patients. Synapse, 2015, 69, 365-374.	1.2	19
50	Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing. Nuclear Medicine and Biology, 2015, 42, 555-560.	0.6	21
51	Amphetamine Decreases Â2C-Adrenoceptor Binding of [11C]ORM-13070: A PET Study in the Primate Brain. International Journal of Neuropsychopharmacology, 2015, 18, pyu081-pyu081.	2.1	13
52	Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates. International Journal of Neuropsychopharmacology, 2015, 18, pyv036.	2.1	34
53	Synthesis of ([11C]carbonyl)raclopride and a comparison with ([11C]methyl)raclopride in a monkey PET study. Nuclear Medicine and Biology, 2015, 42, 893-898.	0.6	18
54	Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinsonâ€™s disease. Brain, 2015, 138, 2687-2700.	7.6	168

#	Article	IF	Citations
55	Diurnal and seasonal variation of the brain serotonin system in healthy male subjects. NeuroImage, 2015, 112, 225-231.	4.2	56
56	Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [11C]MADAM PET study. Psychopharmacology, 2015, 232, 4159-4167.	3.1	9
57	Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2Î²-Carbofluoroethoxy-3Î²-(4â€²-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease. Journal of Nuclear Medicine, 2015, 56, 714-720.	5.0	46
58	Quantification of Blood Flow-Dependent Component in Estimates of Beta-Amyloid Load Obtained Using Quasi-Steady-State Standardized Uptake Value Ratio. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1485-1493.	4.3	27
59	Application of cross-species PET imaging to assess neurotransmitter release in brain. Psychopharmacology, 2015, 232, 4129-4157.	3.1	61
60	Meta-analysis of cognitive performance in drug-naÃ¯ve patients with schizophrenia. Schizophrenia Research, 2014, 158, 156-162.	2.0	209
61	Testâ€“retest reliability of [11C]AZ10419369 binding to 5-HT1B receptors in human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 301-307.	6.4	29
62	Quantitative Analysis of Amyloid Deposition in Alzheimer Disease Using PET and the Radiotracer 11C-AZD2184. Journal of Nuclear Medicine, 2014, 55, 932-938.	5.0	17
63	Distinct regional age effects on [11 C]AZ10419369 binding to 5-HT 1B receptors in the human brain. NeuroImage, 2014, 103, 303-308.	4.2	21
64	Dopamine D1 receptor availability is related to social behavior: A positron emission tomography study. NeuroImage, 2014, 102, 590-595.	4.2	37
65	¹⁸F-MCL-524, an ¹⁸F-Labeled Dopamine D₂ and D₃ Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study. Journal of Nuclear Medicine, 2014, 55, 1164-1170.	5.0	20
66	Reduced 5-HT1B receptor binding in the dorsal brain stem after cognitive behavioural therapy of major depressive disorder. Psychiatry Research - Neuroimaging, 2014, 223, 164-170.	1.8	61
67	Positron emission tomography imaging of 5-hydroxytryptamine1B receptors in Parkinson's disease. Neurobiology of Aging, 2014, 35, 867-875.	3.1	25
68	Quantification of serotonin transporter availability with [11C]MADAM â€" A comparison between the ECAT HRRT and HR systems. NeuroImage, 2012, 60, 800-807.	4.2	47
69	Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects. EJNMMI Research, 2012, 2, 15.	2.5	86
70	Dopamine D1 receptors and age differences in brain activation during working memory. Neurobiology of Aging, 2011, 32, 1849-1856.	3.1	103
71	Development of a PET radioligand for the central 5-HT1B receptor: radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds. Nuclear Medicine and Biology, 2011, 38, 261-272.	0.6	26
72	Antipsychotic Occupancy of Dopamine Receptors in Schizophrenia. CNS Neuroscience and Therapeutics, 2011, 17, 97-103.	3.9	154

#	Article	IF	Citations
73	Quantitative Analysis of [¹¹C]AZ10419369 Binding to 5-HT_{1B} Receptors in Human Brain. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 113-123.	4.3	72
74	Association between striatal and extrastriatal dopamine D2-receptor binding and social desirability. NeuroImage, 2010, 50, 323-328.	4.2	44
75	Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1639-1650.	6.4	173
76	[18F]Flumazenil binding to central benzodiazepine receptor studies by PET. NeuroImage, 2009, 45, 891-902.	4.2	74
77	[11C]Cyclopropyl-FLB 457: A PET radioligand for low densities of dopamine D2 receptors. Bioorganic and Medicinal Chemistry, 2008, 16, 6467-6473.	3.0	7
78	Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum. NeuroImage, 2008, 40, 1287-1295.	4.2	65
79	[11C]AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. NeuroImage, 2008, 41, 1075-1085.	4.2	78
80	Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: A comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride. Synapse, 2006, 59, 260-269.	1.2	108
81	Measurement of serotonin transporter binding with PET and [11C]MADAM: A testâ€“retest reproducibility study. Synapse, 2006, 60, 256-263.	1.2	47
82	Dopamine D2 receptor binding in drug-naÃ¯ve patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Research - Neuroimaging, 2006, 148, 165-173.	1.8	66
83	Synthesis and PET evaluation of (R)-[S-methyl-11C]thionisoxetine, a candidate radioligand for imaging brain norepinephrine transporters. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 1007-1019.	1.0	14
84	Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain, 2006, 129, 2017-2028.	7.6	224
85	[11C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET. Synapse, 2005, 58, 173-183.	1.2	56
86	Effect of amphetamine on dopamine D2 receptor binding in the primate brain with the agonist ligand [11C]MNPA. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S646-S646.	4.3	0
87	Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. NeuroImage, 2004, 22, 794-803.	4.2	92
88	Low Dopamine D2Receptor Binding in Subregions of the Thalamus in Schizophrenia. American Journal of Psychiatry, 2004, 161, 1016-1022.	7.2	115
89	The Serotonin System and Spiritual Experiences. American Journal of Psychiatry, 2003, 160, 1965-1969.	7.2	244
90	Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. International Journal of Neuropsychopharmacology, 2003, 6, 361-370.	2.1	110

#	Article	IF	Citations
91	PET Study of D1Dopamine Receptor Binding in Neuroleptic-Naive Patients With Schizophrenia. American Journal of Psychiatry, 2002, 159, 761-767.	7.2	171
92	Decreased Dopamine D2 Receptor Binding in the Anterior Cingulate Cortex in Schizophrenia. Archives of General Psychiatry, 2002, 59, 25.	12.3	173
93	Wavelet-Aided Parametric Mapping of Cerebral Dopamine D2 Receptors Using the High Affinity PET Radioligand [11C]FLB 457. NeuroImage, 2002, 17, 47-60.	4.2	53
94	SPET imaging of central muscarinic acetylcholine receptors with iodine-123 labelled E-IQNP and Z-IQNP. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 13-24.	2.1	12
95	Dopamine and cognitive functioning: Brain imaging findings in Huntingtonâ€™s disease and normal aging. Scandinavian Journal of Psychology, 2001, 42, 287-296.	1.5	82
96	Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: A PET study. Synapse, 2000, 38, 138-143.	1.2	55
97	Autoradiographic localization of 5-HT2A receptors in the human brain using [3H]M100907 and [11C]M100907. Synapse, 2000, 38, 421-431.	1.2	113
98	Synthesis of [11C]2?-carbomethoxy-3?-(3?-iodo-4?-methyl, -ethyl and isopropyl phenyl)nortropane as potential radiotracers for examination of the serotonin transporter with positron emission tomography. Journal of Labelled Compounds and Radiopharmaceuticals, 2000, 43, 1033-1046.	1.0	1
99	Radiochemical labelling of the dopamine D3 receptor ligand RGH-1756. Journal of Labelled Compounds and Radiopharmaceuticals, 2000, 43, 1069-1074.	1.0	10
100	Age-Related Cognitive Deficits Mediated by Changes in the Striatal Dopamine System. American Journal of Psychiatry, 2000, 157, 635-637.	7.2	383
101	Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neurobiology of Aging, 2000, 21, 683-688.	3.1	313
102	Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. International Journal of Neuropsychopharmacology, 1999, 2, 73-82.	2.1	96
103	Quantification of [11C]FLB 457 Binding to Extrastriatal Dopamine Receptors in the Human Brain. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 1164-1173.	4.3	164
104	Iodine-123 labelled Z -(R , R)-IQNP: a potential radioligand for visualization of M 1 and M 2 muscarinic acetylcholine receptors in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1482-1485.	6.4	10
105	Pindolol binding to 5-HT 1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology, 1999, 144, 303-305.	3.1	44
106	A PET study of D 1 -like dopamine receptor ligand binding. Psychopharmacology, 1999, 146, 220-227.	3.1	63
107	Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with pet in nonhuman primates. , 1999, 31, 154-162.		73
108	Comparison of the Transient Equilibrium and Continuous Infusion Method for Quantitative PET Analysis of [11C]Raclopride Binding. Journal of Cerebral Blood Flow and Metabolism, 1998, 18, 941-950.	4.3	144

#	Article	IF	Citations
109	[carbonyl - 11 C]Desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT 1A receptors in vitro and in vivo. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 338-346.	6.4	54
110	Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 531-534.	6.4	41
111	Bromine-76 and carbon-11 labelled NNC 13-8199, metabolically stable benzodiazepine receptor agonists as radioligands for positron emission tomography (PET). European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 1261-1267.	6.4	14
112	In vitro and in vivo characterisation of nor-?-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 596-601.	2.1	68
113	D2 dopamine receptors and personality traits. Nature, 1997, 385, 590-590.	27.8	198
114	A PET Study of 5-HT2 and D2 Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects. Neuropsychopharmacology, 1997, 16, 1-7.	5.4	117
115	Iodine-123 labeled nor-?-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 25, 19-23.	6.4	59
116	Central 5-HT 2A and D 2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacology, 1997, 131, 339-345.	3.1	22
117	Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Development Research, 1997, 40, 158-170.	2.9	89
118	Effect of reserpine-induced depletion of synaptic dopamine on [11C]Raclopride binding to D2-dopamine receptors in the monkey brain. , 1997, 25, 321-325.		96
119	Initial human studies with single-photon emission tomography using iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine (NNC 13-8241). European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 798-803.	2.1	9
120	Positron Emission Tomography of in-vivo Binding Characteristics of Atypical Antipsychotic Drugs. British Journal of Psychiatry, 1996, 168, 40-44.	2.8	81
121	Effects of cocaine on [11C]norepinephrine and [11C]Î²-CIT uptake in the primate peripheral organs measured by PET. Annals of Nuclear Medicine, 1996, 10, 85-88.	2.2	8
122	Autoradiographic localisation of D 3 -dopamine receptors in the human brain using the selective D 3 -dopamine receptor agonist (+)-[3 H]PD 128907. Psychopharmacology, 1996, 128, 240-247.	3.1	115
123	Characterization of C-11 or I-123 Labelled ?-CIT-FP and ?-CIT-FE Metabolism Measured in Monkey and Human Plasma. Identification of Two Labelled Metabolites with HPLC. Human Psychopharmacology, 1996, 11, 483-490.	1.5	21
124	[11C]?-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography. , 1996, 22, 386-390.		76
125	Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride. Synapse, 1996, 23, 115-123.	1.2	148
126	Synthesis of 2Î²-carbomethoxy-3Î²-(4-[76Br]bromophenyl)tropane ([76Br]Î²-CBT), a pet tracer for in vivo imaging of the dopamine uptake sites. Journal of Labelled Compounds and Radiopharmaceuticals, 1995, 36, 385-392.	1.0	9

#	Article	IF	Citations
127	Lipophilic metabolite of [123I]Î²-CIT in human plasma may obstruct quantitation of the dopamine transporter. Synapse, 1995, 19, 297-300.	1.2	19
128	Variability in D2-dopamine receptor density and affinity: A PET study with [11C]raclopride in man. Synapse, 1995, 20, 200-208.	1.2	176
129	Distribution of D1- and D2-Dopamine Receptors, and Dopamine and Its Metabolites in the Human Brain. Neuropsychopharmacology, 1994, 11, 245-256.	5.4	366
130	Pet study of [11C] Î²-CIT binding to monoamine transporters in the monkey and human brain. Synapse, 1994, 16, 93-103.	1.2	162
131	Metabolism of the PET ligand [11C]SCH 23390. Identification of two radiolabelled metabolites with HPLC. Human Psychopharmacology, 1994, 9, 25-31.	1.5	56
132	PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology, 1993, 113, 149-156.	3.1	121
133	Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biological Psychiatry, 1993, 33, 227-235.	1.3	482
134	Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine. Archives of General Psychiatry, 1992, 49, 538.	12.3	1,357
135	PET Analysis Indicates Atypical Central Dopamine Receptor Occupancy in Clozapine-Treated Patients. British Journal of Psychiatry, 1992, 160, 30-33.	2.8	94
136	[11C]Ro 15-4513, a ligand for visualization of benzodiazepine receptor binding. Psychopharmacology, 1992, 108, 16-22.	3.1	44
137	Ligand metabolites in plasma during PET-studies with the11C-labelled dopamine antagonists, raclopride, SCH 23390 and N-methylspiroperidol. Human Psychopharmacology, 1992, 7, 97-103.	1.5	24
138	11C-SCH 39166, a selective ligand for visualization of dopamine-D1 receptor binding in the monkey brain using PET. Psychopharmacology, 1991, 103, 150-153.	3.1	35
139	Comparison of the In Vitro Receptor Binding Properties of N-[3H]Methylspiperone and [3H]Raclopride to Rat and Human Brain Membranes. Journal of Neurochemistry, 1990, 55, 2048-2057.	3.9	98
140	Maps of receptor binding parameters in the human brain ? a kinetic analysis of PET measurements. European Journal of Nuclear Medicine and Molecular Imaging, 1990, 16, 257-265.	2.1	88
141	Saturation analysis of specific11C Ro 15-1788 binding to the human neocortex using positron emission tomography. Human Psychopharmacology, 1989, 4, 21-31.	1.5	80
142	Raclopride, a new selective ligand for the dopamine-D2 receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1988, 12, 559-568.	4.8	104
143	Central D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated With Antipsychotic Drugs. Archives of General Psychiatry, 1988, 45, 71.	12.3	661
144	The application of positron emission tomography in psychiatry. Nordic Journal of Psychiatry, 1988, 42, 107-110.	0.1	0

#	Article	IF	Citations
145	Transplantation in Parkinson's disease: Two cases of adrenal medullary grafts to the putamen. Annals of Neurology, 1987, 22, 457-468.	5.3	270
146	Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes, 1986, 37, 1039-1043.	0.5	169
147	Imaging of [11C]-labelled RO 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. Journal of Psychiatric Research, 1985, 19, 609-622.	3.1	171